Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer

Masanori Mori; Takashi Yamaguchi; Yoshinobu Matsuda; Kozue Suzuki; Hiroaki Watanabe; Ryo Matsunuma; Jun Kako; Kengo Imai; Yuko Usui; Yoshihisa Matsumoto; David Hui; David Currow; Tatsuya Morita

doi:10.1136/esmoopen-2019-000603

Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer

Masanori Mori, Takashi Yamaguchi, Yoshinobu Matsuda, Kozue Suzuki, Hiroaki Watanabe, Ryo Matsunuma, Jun Kako, Kengo Imai, Yuko Usui, Yoshihisa Matsumoto, David Hui, David Currow, Tatsuya Morita

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

5 Downloads (Pure)

Abstract

Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called € terminal breathlessness'. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research.

Original language	English
Article number	e000603
Number of pages	9
Journal	ESMO Open
Volume	5
Issue number	Suppl 1
DOIs	https://doi.org/10.1136/esmoopen-2019-000603
Publication status	Published - 4 Feb 2020
Externally published	Yes

Bibliographical note

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
commercial re-use. Published by BMJ on behalf of the European Society for Medical
Oncology

Keywords

terminal breathlessness

Access to Document

10.1136/esmoopen-2019-000603Licence: CC BY-NC

Currow_Unanswered_P2020Final published version, 379 KBLicence: CC BY-NC

Cite this

@article{ae1702b35a7948e79b6c8cf6cb784af7,

title = "Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer",

abstract = "Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called € terminal breathlessness'. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research.",

keywords = "terminal breathlessness",

author = "Masanori Mori and Takashi Yamaguchi and Yoshinobu Matsuda and Kozue Suzuki and Hiroaki Watanabe and Ryo Matsunuma and Jun Kako and Kengo Imai and Yuko Usui and Yoshihisa Matsumoto and David Hui and David Currow and Tatsuya Morita",

note = "{\textcopyright} Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology",

year = "2020",

month = feb,

day = "4",

doi = "10.1136/esmoopen-2019-000603",

language = "English",

volume = "5",

journal = "ESMO Open",

issn = "2059-7029",

number = "Suppl 1",

}

TY - JOUR

T1 - Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer

AU - Mori, Masanori

AU - Yamaguchi, Takashi

AU - Matsuda, Yoshinobu

AU - Suzuki, Kozue

AU - Watanabe, Hiroaki

AU - Matsunuma, Ryo

AU - Kako, Jun

AU - Imai, Kengo

AU - Usui, Yuko

AU - Matsumoto, Yoshihisa

AU - Hui, David

AU - Currow, David

AU - Morita, Tatsuya

N1 - © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology

PY - 2020/2/4

Y1 - 2020/2/4

N2 - Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called € terminal breathlessness'. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research.

AB - Breathlessness is among the most common and deteriorating symptoms in patients with advanced cancer, which may worsen towards the end of life. Breathlessness in patients with estimated life expectancy of weeks to days has unique clinical features: it tends to worsen rapidly over days to hours as death approaches often despite current symptom control measures. Breathlessness in patients during the last weeks to days of life can be called € terminal breathlessness'. While evidence has accumulated for the management of breathlessness in patients with cancer who are not dying, such evidence may not be fully applied to terminal breathlessness. Only a few studies have investigated the best practice of terminal breathlessness in patients with cancer. In this paper, we summarise the current evidence for the management of terminal breathlessness, and propose future directions of clinical research.

KW - terminal breathlessness

UR - http://www.scopus.com/inward/record.url?scp=85079367730&partnerID=8YFLogxK

U2 - 10.1136/esmoopen-2019-000603

DO - 10.1136/esmoopen-2019-000603

M3 - Review article

AN - SCOPUS:85079367730

VL - 5

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - Suppl 1

M1 - e000603

ER -

Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this